Halozyme and Roche Enter Agreement for the Application of Enhanze, A Novel Technology to Improve Drug Delivery (RedNova)
BASEL, Switzerland and SAN DIEGO, Dec. 5 /PRNewswire/ -- Halozyme Therapeutics, Inc. and Roche today announced they have entered into an agreement to apply Halozyme's proprietary Enhanze(TM) Technology to Roche's biological therapeutic compounds.

HepaLife's Patented 'PBS-1' Cells for Avian Influenza Vaccine Achieve FDA's Early Guidance Research Objective (Business Wire via Yahoo! Finance)
BOSTON----HepaLife Technologies, Inc. today announced confirmation that the Company's patented 'PBS-1' cells, under development for avian influenza vaccines, are free of pathogens, diseases, bacteria, and potentially harmful viruses.

VIVUS to Present at the 2006 RBC Capital Markets Healthcare Conference (RedNova)
MOUNTAIN VIEW, Calif., Dec. 5 /PRNewswire-FirstCall/ -- VIVUS, Inc. , a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products addressing obesity and sexual health, today announced that Timothy E.